Trends in the Incidence and Prevalence of Parkinson's Disease in Korea: A Nationwide, Population-Based Study by 김신혜
RESEARCH ARTICLE Open Access
Trends in the incidence and prevalence of
Parkinson’s disease in Korea: a nationwide,
population-based study
Joo-Hyun Park1, Do-Hoon Kim1*† , Do-Young Kwon2*†, Moonyoung Choi1, Shinhye Kim3, Jin-Hyung Jung4,
Kyungdo Han4 and Yong-Gyu Park4
Abstract
Background: The lack of adequate and detailed epidemiological data of Parkinson’s disease (PD), especially in Asia,
is a barrier to future disease burdens and the prospect of effective public health plans. This study aimed to
investigate temporal trends in the incidence and prevalence of PD in South Korea from 2010 to 2015, based on
uniform diagnostic criteria.
Methods: This study examined all PD patients registered in a South Korean national registry database of more than
50 million individuals. We analyzed the incidence and prevalence of PD according to age, gender, and region.
Results: The annual incidence of PD was between 22.4–27.8 cases per 100,000 individuals. During the 6-year study
period, there were 73,726 new PD patients, 42.3% of whom were men. The standardized incidence of PD increased
over time in men but remained constant in women until 2013 but began to increase in 2014. The female-to-male
ratio in the incidence of PD was 1.4:1 while the female-to-male ratio in the prevalence of PD was 1.6:1. The age-
and gender-standardized prevalence of PD increased from 115.9 cases per 100,000 individuals in 2010 to 139.8
cases per 100,000 individuals in 2015. From 2014, the incidence and prevalence of PD peaked in individuals aged
between 80 and 89 years in both men and women. Regional analysis also showed an increased prevalence of PD in
all regions of Korea.
Conclusions: The incidence and prevalence of PD in Korea were higher in women and increased gradually from
2010 to 2015. The findings may contribute to epidemiological studies of PD in Asia, and may provide clues on risk
factors for PD.
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Background
The population age structure is changing worldwide
with many countries facing a rapidly ageing population
[1]. As the number of older individuals within a popula-
tion increases, so does the impact of chronic diseases on
public health. Parkinson’s disease (PD) is one of the
most common and complex neurodegenerative disorders
that primarily affects older adults [2]. PD is character-
ized not only by classical parkinsonian motor symptoms,
but also by a range of non-motor features including
autonomic, cognitive, psychiatric, and behavioral dys-
functions [3]. Patients can survive up to a decade after
diagnosis, but as PD progresses most patients experience
severe physical and mental disabilities which impair their
ability to live independently [4]. In addition, the medical
cost of PD is one of the highest among neurological dis-
eases [5, 6]. Thus, this disease poses an increasingly high
physical, emotional, social, and economic burden on pa-
tients, their families and countries [5, 7]. In the face of
rapidly aging societies, reliable epidemiologic data are
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urgently needed to provide insight into the risk factors,
protective factors, and natural history of PD, as well as
providing important information on the burden of this
disease on the population.
Despite many epidemiological studies conducted over
the years, many key aspects of this disease remain unclear.
The estimated incidence and prevalence of PD reported in
previous studies vary to a large extent due to difference in
methodologies, diagnostic criteria, case-finding strategies
and a limited sample size [2, 8]. Temporal trend studies
are particularly rare due to difficulties in the consistent
identification of PD patients in a stable and generalized
population over time. Previous studies have reported that
the incidence of PD increased [9, 10], stabilized [11], or
slightly decreased [12–14] over the years.
The lack of appropriate and detailed epidemiological
data is a barrier for the projection of future disease bur-
den and effective public health planning. Reliable esti-
mates of the prevalence and incidence of PD are needed
for more effective prevention, diagnosis, and manage-
ment. Until recently, most epidemiological studies of PD
were conducted in Western countries [9, 12, 13, 15–18].
The epidemiology of PD in Asian countries is not well
understood, and the comparison of trends in the inci-
dence of PD is limited by a small number of studies with
varying diagnostic criteria [8]. The epidemiology of PD
is known to be different between the East and the West
due to differences in genetics, environmental factors,
and the denominator population [3, 8]. Therefore, fur-
ther research is needed to study the incidence and
prevalence of PD, particularly in Asia.
In this study, we investigated the temporal trends in
the prevalence and incidence of PD in Korea over 6 years
using data from the entire Korean population. The Ko-
rean government established a population-based registry
database called the rare intractable diseases (RID) regis-
tration program, which includes PD. In the RID registry,
all patients are registered after being diagnosed based on
uniform diagnostic criteria that are defined by the gov-
ernment. Thus, using the RID database which is also
linked with national health insurance data allows us to




The data used in this study were extracted from the na-
tional health insurance service (NHIS) database and RID
registry. The NHIS is a mandatory universal health in-
surance system that covers the entire Korean population
[19]. Each medical institution electronically submits all
inpatient and outpatient health care utilization data to
the NHIS for reimbursement purposes. The NHIS has a
registration program for 138 RIDs, including PD, and
offers co-payment reductions to patients for disease-
related expenditure.
All patients with RIDs are required to have their diag-
nosis certified by a physician through the uniform diag-
nostic criteria that are distributed by the NHIS. After
the physician’s assessment, the institution also reviews
the diagnosis before submitting it to the NHIS. This sys-
tematic process ensures that the data regarding RIDs are
reliable. Our study was based on data collected from all
patients with PD in the NHIS-RID database between
January 2010 and December 2015.
Patient selection and diagnostic criteria
We selected all PD patients registered in the RID pro-
gram during the 6-year study period. The diagnostic cri-
teria for PD established by the NHI in the RID program
are similar to the UK PD society brain bank clinical
diagnostic criteria, and are as follows: 1) diagnosis of
Parkinsonian syndrome (Parkinsonism): mild or worse
bradykinesia and at least one of the following: muscular
rigidity, rest tremor, postural instability; 2) the exclusion
criteria for PD: history of strokes, head injury, definite
encephalitis, drug side effects, and hypoxia; 3) supportive
prospective positive criteria for PD: three or more re-
quired for diagnosis of definite PD in combination with
step one: unilateral onset, rest tremor present, progres-
sive disorder, persistent asymmetry affecting the side of
onset most, excellent response (70–100%) to levodopa,
severe levodopa-induced chorea, levodopa response for
5 years or more, clinical course of 10 years or more.
The database did not contain any personal identifiers
as all identifiable personal information in the database
was removed to comply with the privacy rules of the
health insurance portability and accountability act. In-
formed consent was not required for this study as all the
data was obtained from medical records. This study was
performed based on the ethical principles of the Declar-
ation of Helsinki of the World Medical Association. All
procedural and ethical aspects of this study were ap-
proved by the Institutional Review Board of Korea Uni-
versity Ansan Hospital (IRB number: 2017AS0014).
Statistical analysis
An incident case was defined as a newly diagnosed pa-
tient who was registered in the RID program as a PD pa-
tient during a given year. When defining an incident
case, we excluded patients who were diagnosed with PD
within 4 years before their registration in the RID pro-
gram. The annual incidence was calculated by dividing
the total number of incident cases by the total number
of individuals in the entire population on December 31
of each year. These rates were directly standardized by
age and gender to the total Korean population from the
2010 census. Age and gender specific incidences were
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calculated by dividing the number of incident cases in
each age or gender group by the corresponding age or
gender specific population and was expressed as cases
per 100,000 individuals.
We defined a prevalent case as a patient registered
with PD in the NHIS-RID database. When the NHIS
registers the number of prevalent cases in the NHIS-RID
database, it includes those who were registered as inci-
dent cases in the previous year, but does not include the
number of patients who died or were disqualified
(prison, military and immigration) in the previous year.
In addition, prevalent cases of a year include all new pa-
tients registered with PD during a given year.
Age and gender specific prevalence was also calculated
by dividing the number of prevalent cases in each age or
gender group by the corresponding age or gender spe-
cific population and was expressed as cases per 100,000
individuals.
We also analyzed the incidence and prevalence of PD
by metropolitan cities and provinces. In 2015, the ad-
ministrative districts of the Republic of Korea consisted
of eight metropolitan cities (Seoul, Busan, Daegu, In-
cheon, Gwangju, Daejeon, Ulsan and Sejong) and nine
provinces (Gyeonggi, Gangwon, Chungbuk, Chungnam,
Jeonbuk, Jeonnam, Gyeongbuk, Gyeongnam and Jeju).
Results
Incidence
The annual incident cases, incidence, and age or gender
specific incidences of PD are displayed in Table 1 and
Fig. 1a and b. Between 2010 and 2015, 73,726 new PD
patients were registered (31,164 men and 42,562
women). The annual incidence of PD ranged from 22.4
to 27.8 cases per 100,000 individuals. The age- and
gender-standardized incidence of PD was highest in
2015 in both men and women. The standardized inci-
dence of PD in men increased over the study period. In
women, the standardized incidence of PD was relatively
constant until 2013, then increased significantly in 2014.
There was a steady increase in the number of incident
cases in both men and women (Fig. 2b, d). The
incidence among men and women was 20.0 cases per
100,000 individuals and 27.7 cases per 100,000 individ-
uals, respectively, with a female-to-male ratio of 1.4:1.
Among men, the age group with the highest incidence
of PD was between 80 and 89 years (Fig. 2a). In women,
the highest incidence of PD was observed in individuals
aged 70–79 years during 2010–2013 and in those aged
80–89 years from 2014 to 2015 (Fig. 2c). For both men
and women, the incidence rate decreased in individuals
older than 90 years.
Prevalence
Data on the annual prevalence of PD is shown in Table
1, Fig. 1c and d. The number of prevalent PD cases in-
creased from 53,519 in 2010 to 80,747 in 2015, of which
32,002 and 48,745 patients were men and women, re-
spectively. The age- and gender-standardized prevalence
of PD showed a gradual increase in both genders as the
years progressed from 115.9 cases per 100,000 individ-
uals in 2010 to 139.8 cases per 100,000 individuals in
2015. The standardized prevalence in 2015 was higher in
women than in men, with 108.4 cases per 100,000 men
and 170.8 cases per 100,000 women with a female-to-
male ratio of 1.6:1. In men, the prevalence gradually in-
creased with age and peaked at the age of 80–89 years
(Fig. 3a). For women, the peak prevalence was reached
in their 70s in 2010–2011 and in their 80s from 2012
onwards (Fig. 3c).
Age-specific analysis
Table 2 shows the prevalence and incidence of PD in the
individuals under or over 50 years of age. PD is relatively
uncommon in individuals below age 50 and is classified
as young onset Parkinson’s disease when it occurs before
the age of 50 [20]. The incidence of PD increased in in-
dividuals under age 50 years from 1.2 cases per 100,000
individuals in 2010 to 1.7 cases per 100,00 individuals in
2015. The prevalence of PD in this age group also in-
creased from 4.6 cases per 100,00 individuals in 2010 to
5.8 cases per 100,00 individuals in 2015. The prevalence
of PD in the younger age group was higher in men than
Table 1 Incidence and prevalence of Parkinson’s disease in Korea, 2010–2015








Total Total Male Female Total Male Female Total Male Female Total Male Female
2010 50,087 10,606 4294 6312 23.2 18.9 27.4 53,519 20,789 32,730 115.9 90.7 140.8
2011 50,362 10,940 4520 6420 22.9 18.9 26.8 58,504 22,789 35,715 121.5 94.7 147.8
2012 50,675 11,192 4755 6437 22.4 19.0 25.9 63,257 24,718 38,539 125.7 97.8 153.3
2013 50,922 11,897 5083 6814 22.6 19.1 26.1 68,292 26,758 41,534 128.5 99.5 157.1
2014 51,187 13,253 5725 7528 24.2 20.6 27.8 74,082 29,051 45,031 133.9 103.3 164.1
2015 51,473 15,838 6787 9051 27.8 23.3 32.2 80,747 32,002 48,745 139.8 108.4 170.8
a Age- and sex- adjusted to 2010 population
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Fig. 1 Trends in the incidence and prevalence of Parkinson’s disease (PD) in Korea, 2010–2015. a Incidence of PD, b incident cases of PD, c
prevalence of PD, d prevalent cases of PD.
Fig. 2 Incidence of Parkinson’s disease according to age and gender in Korea, 2010–2015. a Incidence in men, b incident cases in men, c
incidence in women, d incident cases in women
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in women. Under the age of 50, the female-to-male ratio
of the incidence and prevalence of PD in 2015 were 0.9:
1 and 0.8: 1, respectively.
In individuals aged 50 and older, the incidence of
PD increased from 73.2 cases per 100,00 individuals
in 2010 to 88.7 cases per 100,00 individuals in 2015.
The prevalence of PD in this age group increased
from 371.3 cases per 100,00 individuals in 2010 to
455.7 cases per 100,00 individuals in 2015. In this
older age group, the incidence and prevalence of PD
were higher in women than in men, and the female-
to-male ratios in 2015 were 1.2: 1 and 1.4: 1,
respectively.
Regional analysis of trends
Table 3 and Fig. 4 show the trends in age-and sex-
standardized incidence and prevalence of PD per 100,00
individuals by 17 regions from 2010 to 2015. During this
period, the age-and sex-standardized incidence of PD in-
creased in all regions of the country except for Sejong-si.
Sejong-si was separated from provinces Chungbuk and
Chungnam as a new administrative metropolitan city in
2012. Gyeongbuk and Jeonbuk experienced the largest
increase in the incidence of PD from 2010 to 2015. The
incidence ratios (2010 to 2015) of these two regions
were 1.6 and 1.5, respectively. The highest incidence of
PD was recorded in Jeju (31.7 cases per 100,00 individ-
uals) in 2010 and Jeonbuk (38.1 cases per 100,00 individ-
uals) in 2015.
The age-and sex-standardized prevalence of PD in-
creased in all regions from 2010 to 2015. The largest in-
crease was recorded in Jeonbuk with a prevalence ratio
of 1.4 from 2010 to 2015. The highest prevalence of PD
was in Seoul in 2010 (130.7 cases per 100,00 individuals),
and in Jeonbuk in 2015 (169.0 cases per 100,00 individ-
uals). The region with the lowest prevalence of PD was
Chungbuk. (93.7 cases per 100,00 individuals in 2010
and 113.4 cases per 100,00 individuals in 2015).
Discussion
Our study was performed using recent population-based
data encompassing the entire population of Korea. This
is currently the only nationwide epidemiological study of
PD in Korea. Furthermore, to the best of our knowledge,
this is the first nationwide study that employed data
from an entire population using uniform diagnostic cri-
teria to assess recent temporal trends in the incidence
and prevalence of PD in Asia.
Our results indicate an increasing trend in the annual
prevalence and incidence rates of PD over the past 6
years. In our study, there were 16,152 new PD cases
from 2010 to 2015, with a mean annual incidence of
23.9 cases per 100,000 individuals. The incidence of PD
in men steadily increased throughout the study period.
Conversely, the trend remained stable in women until
2013, then an increase in the incidence of PD was ob-
served from 2014 onwards. The number of actual inci-
dent cases also gradually increased in both men and
Fig. 3 Prevalence of Parkinson’s disease according to age and gender in Korea, 2010–2015. a Prevalence in men, b prevalent cases in men, c
prevalence in women, d prevalent cases in women
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women. The lack of a clear trend in the incidence rate
across the genders may be due to a difference in the de-
nominator population caused by the growing aging
population, especially among women.
Similar to our findings, several previous studies also re-
ported an increase in the incidence of PD over time. In a
30-year study conducted in Olmsted County, Minnesota,
Savica et al. [9] reported that the incidence of PD in-
creased in men and remained stable in women. Only a
few other studies evaluating trends in the incidence of PD
have been conducted in the United Kingdom [13, 17],
United States [9, 11], Netherlands [12], France [16], and
Taiwan [10, 14]. These studies reported either a stable
incidence [11, 16], a slight decrease [12–14, 17], or an in-
crease [9, 10] in the incidence of PD over time. However,
most of these studies [10, 11, 13, 14, 16] identified patients
with PD through algorithmic searches of administrative
databases without using reliable uniform diagnostic cri-
teria. There is a substantial potential for misclassification
when using this approach, making the results of these
studies difficult to interpret.
The first possible cause for an increase in the incidence
rate of PD is an increasingly older population. As PD is a
neurodegenerative disease, increased incidence is expected
in an ageing population [21]. The second possible explan-
ation is an increased awareness of PD in patients and physi-
cians as well as the availability of co-payments through the
RID program. This leads to the diagnosis of previously un-
diagnosed cases and swifter referrals of patients with PD. In
other words, there is a growing willingness to consult doc-
tors regarding symptoms that were previously considered a
normal part of aging which increases the likelihood that pa-
tients are examined by a neurologist. However, given the
different trends observed in men and women and our con-
sistent patient identification strategy, the observed increase
is likely to be a real increase in incidence and prevalence.
We observed a gradual increase in the prevalence of PD
throughout the study period. Similar results have also
been reported in studies conducted in Japan [22], Taiwan
[10, 14], and France [16] in the past decade. Both changes
in the incidence of PD over time and the survival time of
individuals with PD affect the prevalence of PD [23].
Table 2 Incidence and prevalence of Parkinson’s disease (PD) according to age in Korea, 2010–2015
Incidence Prevalence
2010 2011 2012 2013 2014 2015 2010 2011 2012 2013 2014 2015
0–49 years
Total
Cases 435 422 412 403 520 590 1663 1663 1643 1680 1826 1974
Ratea 1.2 1.2 1.2 1.2 1.5 1.7 4.6 4.7 4.6 4.8 5.3 5.8
Male
Cases 234 238 232 224 282 326 929 939 926 950 1023 1104
Ratea 1.3 1.3 1.3 1.2 1.6 1.8 5 5.1 5.1 5.3 5.7 6.2
Female
Cases 201 184 180 179 238 264 734 724 717 730 803 870
Ratea 1.1 1.1 1.1 1.1 1.4 1.6 4.2 4.2 4.2 4.3 4.8 5.2
> 50 years
Total
Cases 10,171 10,518 10,780 11,494 12,733 15,248 51,856 56,841 61,614 66,612 72,256 78,773
Ratea 73.2 72 70.3 71.9 76.9 88.7 371.3 386.9 399.9 414.4 433.9 455.7
Male
Cases 4060 4282 4523 4859 5443 6461 19,860 21,850 23,792 25,808 28,028 30,898
Ratea 63.1 63.1 63.4 65.1 70.2 80.1 307.5 320.7 332 344.1 359.8 381.3
Female
Cases 6111 6236 6257 6635 7290 8787 31,996 34,991 37,822 40,804 44,228 47,875
Ratea 81.9 79.7 76.4 77.9 82.8 96.4 426.1 444.2 458.9 475.9 499 521.4
aRate = Cases/ Population of that age group *100,000
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Interestingly, the present study demonstrated a pre-
ponderance in the prevalence and incidence of PD in the
female population. Previous studies conducted on West-
ern populations seem to indicate that PD is predominant
in males [9, 13, 17, 18]. However, many Asian studies
have reported female preponderance in PD [22, 24–28],
while only some studies showed only male preponder-
ance [14], or no difference between the genders [10, 29].
The reasons for this discrepancy are unclear and may be
the results of several compounding factors. First, Asian
individuals have different genetic susceptibilities and ex-
perience different environmental factors. Second, Asian
women may face more risk factors, such as pesticide use,
head trauma, agricultural occupations, toxic exposure,
dietary deficiencies, and well-water drinking. Alterna-
tively Asian women may also have fewer preventing fac-
tors, such as smoking, coffee drinking, and alcohol
consumption compared to Western women [3]. Third,
the ageing female population is increasing more rapidly
than the male population [1]. Finally, men are more
likely to be underdiagnosed because they have more
competing diseases than women.
The incidence and prevalence of PD were higher in
women than in men in patients over the age of 50, and
higher in men than in women in patients with young on-
set PD. The neuroprotective effect of estrogen [30] is
speculated to be the reason for the higher incident rate
in male patients with young onset PD. However, the
protective effects of estrogen decrease after menopause
likely causing the observed increase in the incidence and
prevalence of PD in the aging post-menopausal female
population.
PD rarely developed before 50 years old, and the inci-
dence increased sharply in patients in their 60s. The
number of PD cases was highest in both male and fe-
male patients in their 70s during the entire study period.
In the male population, the prevalence and incidence of
PD consistently peaked between 80 and 89 years. In the
female population, the peak prevalence and incidence of
PD was between 70 and 79 years in 2010 and then in-
creased to 80 and 89 years between 2012 and 2014. Any
positive changes made in environmental risk factors in
women seem to delay the onset of PD.
From 2010 to 2015, the prevalence of PD increased in
all regions of the country. The incidence of PD also in-
creased in all regions except for Sejong-si (a new admin-
istrative metropolitan city separated in 2012). In 2015,
the highest incidence and prevalence of PD was in Jeon-
buk province. These findings can be utilized by policy
makers to prioritize advancements in national health.
This study has certain strengths. First, this is a nation-
wide study that surveyed the entire population of Korea
for 6 years. This nationwide evaluation of the epidemio-
logical features of PD provides a better understanding of
Table 3 Age-and sex-standardized incidence and prevalence per 100,000 population by region from 2010 to 2015
Incidence Prevalence
2010 2011 2012 2013 2014 2015 Incidence ratioa
(2010–5)
2010 2011 2012 2013 2014 2015 Prevalence ratioa
(2010–5)
Seoul 24.9 22.0 22.0 23.2 24.6 28.7 1.2 130.7 132.5 137.0 138.2 143.0 148.6 1.1
Busan 24.1 22.8 22.6 25.5 27.7 30.9 1.3 115.6 124.9 131.2 134.7 142.6 150.2 1.3
Daegu 19.8 20.5 19.7 19.9 20.4 23.7 1.2 112.8 118.1 122.0 120.0 123.2 126.2 1.1
Incheon 19.4 18.5 17.8 20.4 21.6 25.5 1.3 106.3 112.8 113.5 117.9 122.8 129.5 1.2
Gwangju 22.3 23.9 21.1 19.7 24.5 28.9 1.3 117.7 132.9 134.2 132.8 140.8 146.5 1.2
Daejeon 21.0 26.8 27.8 26.6 22.5 26.0 1.2 113.9 128.3 140.0 144.2 147.3 147.9 1.3
Ulsan 23.4 20.8 17.4 21.4 24.2 25.7 1.1 107.5 113.0 118.9 123.6 129.5 133.7 1.2
Sejong . . . 24.2 20.8 14.5 0.6 . . . 124.9 135.9 133.3 1.1
Gyeonggi 24.2 24.7 23.2 23.1 24.4 27.8 1.1 121.7 130.0 134.9 136.8 141.4 145.5 1.2
Gangwon 20.6 21.5 17.4 23.1 27.2 24.3 1.2 105.9 112.4 112.0 116.5 125.4 125.0 1.2
Chungbuk 20.3 21.6 17.9 20.1 18.3 22.9 1.1 93.7 104.2 102.2 105.4 108.2 113.4 1.2
Chungnam 24.1 23.6 24.3 22.4 24.7 25.3 1.0 109.5 118.5 124.7 126.5 132.7 136.7 1.2
Jeonbuk 26.2 24.5 27.8 28.4 32.9 38.1 1.5 124.4 127.1 136.8 143.3 153.5 169.0 1.4
Jeonnam 23.1 23.2 21.7 20.4 21.5 26.4 1.1 101.6 110.4 114.3 115.5 119.1 127.5 1.3
Gyeongbuk 18.9 21.2 20.9 21.0 23.0 29.8 1.6 97.1 103.0 110.2 113.1 119.0 129.4 1.3
Gyeongnam 23.3 23.0 21.0 22.2 23.9 26.2 1.1 105.6 112.7 115.2 121.1 125.5 130.5 1.2
Jeju 31.7 39.0 27.9 22.9 28.7 31.0 1.0 129.1 149.3 154.8 151.2 156.7 162.7 1.3
Rate = cases/the population of the region*100,000
aIncidence of 2015/incidence of 2010 or Prevalence of 2015/ prevalence of 2010
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the national patterns of PD epidemiology in South
Korean patients with a recent diagnosis of PD. This
study had no selection bias as it examined a stable and
generalized population. Second, the epidemiological data
in this study is more reliable than the data reported in
previous studies because clear and uniform diagnostic
criteria were used. Most previous nationwide studies
used algorithmic searches of administrative databases to
diagnose PD patients leading to potential misclassifica-
tion depending on the different algorithms used. To the
best of our knowledge, this study is the first Asian study
to examine long-term trends in the incidence of PD
using uniform and reliable diagnostic criteria.
This study also has a few limitations. First, because we
used insurance claims data, we could not rule out the
possibility of the misclassification of patients with PD.
However, the diagnosis of PD in the RID database is
based on diagnostic criteria standardized in hospitals by
the NHI. Before being submitted to the NHI, the physi-
cian’s diagnosis passes through a verification process
and is reviewed by another health care personnel in their
institution. Through this process, we are certain that a
Fig. 4 Regional trends in age- and sex-standardized incidence and prevalence per 100,000 population from 2010 to 2015. a Incidence in 2010, b
Incidence in 2015, c Prevalence in 2010, d Prevalence in 2015. (The maps depicted in Figure 4 were produced by Joo-Hyun, Park.)
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diagnosis in the RID database has a relatively higher ac-
curacy than other insurance data. This is also confirmed
by other epidemiological studies of RID, in which a high
agreement has been reported between hospital and ad-
ministration data [31, 32]. Although neuropathological
assessment is the gold standard for diagnosis of PD, there
are no generally accepted standard pathological diagnostic
criteria for PD [33], and the diagnosis of PD relies on clin-
ical examination [3, 34]. Second, we could not identify the
stage of PD in this study. Third, the diagnosis of PD is
likely to be underestimated because of low hospital
utilization or other comorbid diseases in older patients
[15]. There may be an unknown number of individuals
with PD who were not accurately diagnosed because of in-
adequate facilities and staffing in areas of low socioeco-
nomic status. Although other studies have used several
methods to calculate the number of patients with PD in a
community, there is no gold standard and each method
has its own limitations [35, 36]. Fourth, we could not iden-
tify risk factors because we were unable to access the
underlying disease information of PD patients. Therefore,
we were unable to directly examine whether changes in
environmental risk factors, such as a decreased prevalence
of smoking, were responsible for the observed increase in
the incidence of PD. Finally, the number of prevalent cases
in that year excluded not only the number of patients who
died, but also the number of people who have become dis-
qualified (prison, military, immigration, etc.) in the previ-
ous year. Currently, the NHIS-RID database does not
provide information on insurance disqualification. Hence,
the observed prevalence may be affected by the number of
deaths and the number of people disqualified each year.
However, the difference caused by this discrepancy will
not be large. The results of this study will contribute
greatly to further research by presenting precise macro-
scopic epidemiologic data.
Conclusion
In Korea, the prevalence and incidence of PD has gradually
increased in recent years. Over this period, PD occurred
more in women than in men. This study will aid the assess-
ment of disease burden and resource allocation in PD. Fur-
thermore, a thorough analysis of this trend may provide
clues on the environmental factors involved in the etiology
and characteristics of PD in Korea. To acquire a better un-
derstanding on the effects of multiple potential risk factors
on PD, in-depth studies on the role of genetic and environ-
mental factors in the epidemiology of PD are required.
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